Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2546)	1/12/2001 11:02:23 AM
From: keokalani'nui	Read Replies (1) of 52153

Peter. Super idea to split off the diseases. With soluble receptors, Mab antagonists, agonists, small molecules, fusion proteins and so on, the mind can only organize it all around the ultimate label. Plus, it would be the best framework for comparing clinical data between competitors. Another alternative would be: For each company, we could divide the company thread into its targeted indications and leave the main thread for financings, valuation, and potshots. If the same drug has multiple markets, we could open threads for each market and cross reference the one where all the talk takes place. It would be very important to make sure they all were in a row on the main menu. --Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next